Supernus Pharmaceuticals Dirección

Dirección controles de criterios 2/4

El CEO de Supernus Pharmaceuticals' es Jack Khattar , nombrado en Jan 2005, tiene una permanencia de 19.25 años. compensación anual total es $10.01M, compuesta por 9.1% salario y 90.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.54% de las acciones de la empresa, por valor de €54.02M. La antigüedad media del equipo directivo y de la junta directiva es de 8.8 años y 13.3 años, respectivamente.

Información clave

Jack Khattar

Chief Executive Officer (CEO)

US$13.3m

Compensación total

Porcentaje del salario del CEO	7.3%
Permanencia del CEO	19.3yrs
Participación del CEO	3.5%
Permanencia media de la dirección	9.1yrs
Promedio de permanencia en la Junta Directiva	13.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jack Khattar en comparación con los beneficios de Supernus Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$13m	US$963k	US$1m
Sep 30 2023	n/a	n/a	US$26m
Jun 30 2023	n/a	n/a	US$43m
Mar 31 2023	n/a	n/a	US$52m
Dec 31 2022	US$10m	US$914k	US$61m
Sep 30 2022	n/a	n/a	US$38m
Jun 30 2022	n/a	n/a	US$57m
Mar 31 2022	n/a	n/a	US$73m
Dec 31 2021	US$8m	US$870k	US$53m
Sep 30 2021	n/a	n/a	US$82m
Jun 30 2021	n/a	n/a	US$100m
Mar 31 2021	n/a	n/a	US$111m
Dec 31 2020	US$7m	US$836k	US$127m
Sep 30 2020	n/a	n/a	US$129m
Jun 30 2020	n/a	n/a	US$118m
Mar 31 2020	n/a	n/a	US$116m
Dec 31 2019	US$8m	US$812k	US$113m
Sep 30 2019	n/a	n/a	US$106m
Jun 30 2019	n/a	n/a	US$105m
Mar 31 2019	n/a	n/a	US$103m
Dec 31 2018	US$7m	US$724k	US$111m
Sep 30 2018	n/a	n/a	US$99m
Jun 30 2018	n/a	n/a	US$87m
Mar 31 2018	n/a	n/a	US$73m
Dec 31 2017	US$6m	US$614k	US$57m

Compensación vs. Mercado: La compensación total de Jack($USD10.01M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.63M).

Compensación vs. Ingresos: La compensación de Jack ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Jack Khattar (62 yo)

19.3yrs

Permanencia

US$13,278,093

Compensación

Mr. Jack A. Khattar founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as Chief Executive Officer, President, Secretary and Director since 2005. He serves as...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jack Khattar	Founder	19.3yrs	US$13.28m	3.52% $ 55.5m
Timothy Dec	Senior VP & CFO	2.8yrs	US$2.38m	0.013% $ 205.9k
Padmanabh Bhatt	Chief Scientific Officer & Senior VP of Intellectual Property	12.2yrs	US$1.47m	0.016% $ 245.4k
Frank Mottola	Senior Vice President of Quality	4.3yrs	US$1.79m	0.014% $ 222.7k
Jonathan Rubin	Senior VP of Research & Development and Chief Medical Officer	4.3yrs	US$1.59m	0.0084% $ 132.8k
Kevin Anderson	Compliance Officer	12.3yrs	sin datos	sin datos
Todd Horich	Senior Vice President of Marketing & Market Access	9.3yrs	sin datos	sin datos
Taylor Raiford	Senior Vice President of Sales	9.3yrs	sin datos	sin datos
Bryan Roecklein	Senior Vice President of Corporate Development	8.8yrs	sin datos	sin datos
Jeff Bozick	Senior Vice President of Supply Chain	3yrs	sin datos	sin datos

9.1yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de S49 es experimentado (8.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jack Khattar	Founder	19.3yrs	US$13.28m	3.52% $ 55.5m
Charles Newhall	Independent Chairman of the Board	19.3yrs	US$407.02k	0.22% $ 3.5m
John Siebert	Independent Director	13.3yrs	US$392.52k	0.16% $ 2.5m
Georges Gemayel	Independent Director	9.2yrs	US$378.52k	0.031% $ 492.5k
Carrolee Barlow	Independent Director	5.9yrs	US$376.02k	0.031% $ 492.5k
Frederick Hudson	Independent Director	14.3yrs	US$385.02k	0.068% $ 1.1m
Bethany Sensenig	Independent Director	less than a year	US$514.39k	sin datos

13.3yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de S49 son experimentados ( 13.3 años antigüedad media).

Supernus Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Supernus Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Supernus Pharmaceuticals, Inc. Appoints Bethany L. Sensenig to Board of Directors

Senior Vice President of Quality recently sold €160k worth of stock

Insufficient new directors

Insufficient new directors

Supernus Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2022

Recent updates

Supernus Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Supernus Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023

Full year 2023 earnings released: EPS: US$0.024 (vs US$1.13 in FY 2022)

Supernus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

New minor risk - Insider selling

Investor sentiment improves as stock rises 15%

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.033 profit in 3Q 2022)

Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Supernus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Supernus Pharmaceuticals, Inc. Resubmits NDA for SPN-830 Apomorphine Infusion Device

Supernus Pharmaceuticals, Inc. Announces New Qelbree®? Data Showing Improvement in ADHD Symptoms

Supernus Pharmaceuticals, Inc. Appoints Bethany L. Sensenig to Board of Directors

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.015 loss per share (vs US$0.15 profit in 2Q 2022)

Supernus Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2023

Supernus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) dropped from Russell 2000 Value-Defensive Index

First quarter 2023 earnings released: EPS: US$0.31 (vs US$0.48 in 1Q 2022)

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

Senior Vice President of Quality recently sold €160k worth of stock

Full year 2022 earnings released: EPS: US$1.13 (vs US$1.01 in FY 2021)

Supernus Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Insufficient new directors

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022

Supernus Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Supernus Pharmaceuticals, Inc. Provides Regulatory Update on SPN-830

Insufficient new directors

Supernus Pharmaceuticals, Inc. Provides Earning Guidance for Full Year 2022

Supernus Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Supernus Pharmaceuticals, Inc. announced delayed 10-Q filing

Supernus Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2022

Supernus Pharmaceuticals, Inc. Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults

Supernus Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2022

Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year of 2022

Supernus Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Supernus Pharmaceuticals, Inc. Resubmits NDA for SPN-830 Apomorphine Infusion Device

Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN) completed the acquisition of Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS) from Mohr Davidow Ventures and others.

Third quarter 2021 earnings released: EPS US$0.41 (vs US$0.76 in 3Q 2020)

Investor sentiment improved over the past week

Supernus Pharmaceuticals, Inc. Announces Qelbree sNDA for Adult Indication Accepted for Review by FDA

Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for Full Year 2021

Second quarter 2021 earnings released: EPS US$0.45 (vs US$0.66 in 2Q 2020)

Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) dropped from Russell 3000 Growth Index

Supernus Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Treatment Qelbree for the Treatment of Attention-Deficit Hyperactivity Disorder in Pediatric Patients

Supernus Pharmaceuticals, Inc. Reiterates Full Year 2021 Financial Guidance

Supernus Pharmaceuticals, Inc. announced delayed annual 10-K filing

Full year 2020 earnings released: EPS US$2.41 (vs US$2.16 in FY 2019)

Revenue misses expectations

Supernus Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA

Supernus Pharmaceuticals, Inc. Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients

New 90-day high: €24.80

Investor sentiment improved over the past week

New 90-day high: €21.80

Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD

New 90-day high: €21.60

Investor sentiment improved over the past week

Supernus Pharmaceuticals, Inc. Announces Executive Changes

Supernus Pharmaceuticals, Inc. Provides Regulatory Updates for SPN-812 and SPN-830

Revenue beats expectations

Third quarter 2020 earnings released: EPS US$0.76

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2020

Supernus Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 03, 2020

Supernus Pharmaceuticals, Inc. Announces Executive Changes

Supernus Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 18, 2020

Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN) acquired USWM Enterprises, LLC from US WorldMeds, LLC.

Análisis de compensación del CEO